• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

浸润肾细胞癌的活化γ/δ T淋巴细胞。

Activated gamma/delta T lymphocytes infiltrating renal cell carcinoma.

作者信息

Kowalczyk D, Skorupski W, Kwias Z, Nowak J

机构信息

Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland.

出版信息

Immunol Lett. 1996 Oct;53(1):15-8. doi: 10.1016/0165-2478(96)02605-3.

DOI:10.1016/0165-2478(96)02605-3
PMID:8946212
Abstract

Gamma/delta (gamma delta) T lymphocytes have been postulated to play a role in a surveillance mechanism that eliminates transformed or otherwise damaged cells. In this study, we examined by flow cytometry the frequency and phenotype of gamma delta T cells in the tumour infiltrating lymphocytes (TIL) and peripheral blood (PBL) from renal cell carcinoma patients. The TCR gamma delta + cells comprised an average of 3.8% of the CD3+ TIL and 5.2% of circulating T cells. Analysis of surface immunophenotype revealed that activation markers of T lymphocytes: CD25 and HLA DR were highly expressed on the tumour infiltrating gamma delta + T lymphocytes (median 27.6% for CD25 and 52.0% for HLA DR). More importantly, percentage of activated gamma delta T cells was found to be much higher than compared to all activated CD3+ cells. Furthermore, an unusually high proportion of gamma delta positive TILs express CD4 or CD8 molecules (17.2 and 36.8%, respectively), indicating that they might recognise antigen presented within MHC II or I context. These results suggest that gamma delta T lymphocytes may play a certain role in immune response against tumour cells.

摘要

γ/δ(伽马/德尔塔)T淋巴细胞被推测在一种清除转化细胞或其他受损细胞的监视机制中发挥作用。在本研究中,我们通过流式细胞术检测了肾细胞癌患者肿瘤浸润淋巴细胞(TIL)和外周血(PBL)中γδ T细胞的频率和表型。TCRγδ +细胞平均占CD3 + TIL的3.8%和循环T细胞的5.2%。表面免疫表型分析显示,T淋巴细胞的激活标志物:CD25和HLA DR在肿瘤浸润的γδ + T淋巴细胞上高表达(CD25中位数为27.6%,HLA DR为52.0%)。更重要的是,发现活化的γδ T细胞百分比比所有活化的CD3 +细胞高得多。此外,γδ阳性TIL中异常高比例表达CD4或CD8分子(分别为17.2%和36.8%),表明它们可能识别在MHC II或I背景下呈递的抗原。这些结果表明,γδ T淋巴细胞可能在针对肿瘤细胞的免疫反应中发挥一定作用。

相似文献

1
Activated gamma/delta T lymphocytes infiltrating renal cell carcinoma.浸润肾细胞癌的活化γ/δ T淋巴细胞。
Immunol Lett. 1996 Oct;53(1):15-8. doi: 10.1016/0165-2478(96)02605-3.
2
Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma.肾细胞癌患者肿瘤浸润淋巴细胞的流式细胞术分析
Br J Urol. 1997 Oct;80(4):543-7. doi: 10.1046/j.1464-410x.1997.00408.x.
3
Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.人肾细胞癌中新鲜(未培养)肿瘤浸润性T淋巴细胞的表型、细胞因子产生及细胞溶解能力
Clin Exp Immunol. 1997 Sep;109(3):501-9. doi: 10.1046/j.1365-2249.1997.4771375.x.
4
Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.与子宫颈癌患者肿瘤引流淋巴结及外周血中的淋巴细胞相比,肿瘤浸润淋巴细胞含有更多数量的1型细胞因子表达细胞和DR+T细胞。
Gynecol Oncol. 2001 Jun;81(3):424-32. doi: 10.1006/gyno.2001.6200.
5
Identification of an enriched CD4+ CD8alpha++ CD8beta+ T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma.在人肾细胞癌肿瘤浸润淋巴细胞中鉴定出一个富集的CD4+ CD8α++ CD8β+ T细胞亚群。
Int J Cancer. 1997 Apr 10;71(2):178-82. doi: 10.1002/(sici)1097-0215(19970410)71:2<178::aid-ijc9>3.0.co;2-y.
6
Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma.肾癌患者肿瘤浸润淋巴细胞及外周血淋巴细胞的表型分析
Acta Medica (Hradec Kralove). 2007;50(3):207-12.
7
Memory T-lymphocytes are the main population of tumor-infiltrating lymphocytes obtained from human primary liver tumors.记忆性T淋巴细胞是从人类原发性肝癌中获取的肿瘤浸润淋巴细胞的主要群体。
J Hepatol. 1992 Sep;16(1-2):197-202. doi: 10.1016/s0168-8278(05)80115-1.
8
T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients.乳腺癌患者淋巴细胞群体上的T细胞受体γ/δ表达
Immunol Lett. 1992 Feb 15;31(3):279-83. doi: 10.1016/0165-2478(92)90127-a.
9
Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers.肾细胞癌 (RCC) 肿瘤表现出大量表达衰竭标志物的双阳性 (DP) CD4+CD8+T 细胞的扩增。
Front Immunol. 2018 Nov 26;9:2728. doi: 10.3389/fimmu.2018.02728. eCollection 2018.
10
[Monitoring of anti-tumour cell-mediated response in patients with renal cell carcinoma, disturbance of T cell proliferation].[肾细胞癌患者抗肿瘤细胞介导反应的监测,T细胞增殖紊乱]
Vnitr Lek. 2008 Feb;54(2):139-45.

引用本文的文献

1
A new prognostic model based on gamma-delta T cells for predicting the risk and aiding in the treatment of clear cell renal cell carcinoma.一种基于γδT细胞的新预后模型,用于预测透明细胞肾细胞癌的风险并辅助其治疗。
Discov Oncol. 2024 May 25;15(1):185. doi: 10.1007/s12672-024-01057-2.
2
Tumor Lipids of Pediatric Papillary Renal Cell Carcinoma Stimulate Unconventional T Cells.儿科乳头状肾细胞癌的肿瘤脂质可刺激非传统 T 细胞。
Front Immunol. 2020 Aug 20;11:1819. doi: 10.3389/fimmu.2020.01819. eCollection 2020.
3
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.
白细胞介素-2 和唑来膦酸联合增强 γδ T 细胞治疗难治性肾细胞癌的初步试验。
Cancer Immunol Immunother. 2011 Oct;60(10):1447-60. doi: 10.1007/s00262-011-1049-8. Epub 2011 Jun 7.
4
NK cells and gammadelta T cells mediate resistance to polyomavirus-induced tumors.自然杀伤细胞和 gammadelta T 细胞介导对多瘤病毒诱导的肿瘤的抵抗。
PLoS Pathog. 2010 May 27;6(5):e1000924. doi: 10.1371/journal.ppat.1000924.
5
Genomic expression analysis by single-cell mRNA differential display of quiescent CD8 T cells from tumour-infiltrating lymphocytes obtained from in vivo liver tumours.通过对从体内肝肿瘤获取的肿瘤浸润淋巴细胞中静止CD8 T细胞进行单细胞mRNA差异显示来进行基因组表达分析。
Immunology. 2009 May;127(1):83-90. doi: 10.1111/j.1365-2567.2008.02926.x.
6
Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma.γδ T淋巴细胞在肾细胞癌中的相关性存疑。
J Immunol. 2008 Mar 1;180(5):3578-84. doi: 10.4049/jimmunol.180.5.3578.